Business Description
Acurx Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00510M1045
Share Class Description:
FRA:3ZO: Ordinary SharesDescription
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.52 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -33.6 | |||||
| 3-Year EPS without NRI Growth Rate | -33.6 | |||||
| 3-Year FCF Growth Rate | -30.1 | |||||
| 3-Year Book Growth Rate | 4.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -25.77 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.79 | |||||
| 9-Day RSI | 48.38 | |||||
| 14-Day RSI | 46.58 | |||||
| 6-1 Month Momentum % | 2.67 | |||||
| 12-1 Month Momentum % | -59.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.09 | |||||
| Quick Ratio | 2.09 | |||||
| Cash Ratio | 2.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.9 | |||||
| Shareholder Yield % | -15.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -345.03 | |||||
| ROA % | -210.22 | |||||
| ROIC % | -8200.98 | |||||
| 3-Year ROIIC % | -2612.04 | |||||
| ROCE % | -345.02 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 8.74 | |||||
| Price-to-Tangible-Book | 9 | |||||
| EV-to-EBIT | -1.47 | |||||
| EV-to-EBITDA | -1.47 | |||||
| EV-to-FCF | -1.96 | |||||
| Price-to-Net-Current-Asset-Value | 9 | |||||
| Price-to-Net-Cash | 9.5 | |||||
| Earnings Yield (Greenblatt) % | -68.17 | |||||
| FCF Yield % | -39.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acurx Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.073 | ||
| Beta | -3.92 | ||
| Volatility % | 35.07 | ||
| 14-Day RSI | 46.58 | ||
| 14-Day ATR (€) | 0.071256 | ||
| 20-Day SMA (€) | 1.756 | ||
| 12-1 Month Momentum % | -59.32 | ||
| 52-Week Range (€) | 1.486 - 4.72 | ||
| Shares Outstanding (Mil) | 16.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acurx Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acurx Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Acurx Pharmaceuticals Inc Frequently Asked Questions
What is Acurx Pharmaceuticals Inc(FRA:3ZO)'s stock price today?
The current price of FRA:3ZO is €1.71. The 52 week high of FRA:3ZO is €4.72 and 52 week low is €1.49.
When is next earnings date of Acurx Pharmaceuticals Inc(FRA:3ZO)?
The next earnings date of Acurx Pharmaceuticals Inc(FRA:3ZO) is 2024-11-13.
Does Acurx Pharmaceuticals Inc(FRA:3ZO) pay dividends? If so, how much?
Acurx Pharmaceuticals Inc(FRA:3ZO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers